FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032568536> ?p ?o ?g. }

• W2032568536 endingPage "630.e8" @default.
• W2032568536 startingPage "630.e1" @default.
• W2032568536 abstract "Objective Soluble receptor levels of tumor necrosis factor (sTNF-R)-1 and -2 are increased during preeclampsia. We postulated the increase preceded overt disease. Study Design Archived plasma from the Eunice Kennedy Shriver National Institute of Child Health and Human Development aspirin to prevent preeclampsia in high risk women trial were used to measure serial sTNF-R1 and sTNF-R2 (enrollment, 24-28 week's gestation) in 986 women (577 also sampled at 34-38 weeks). Results Preeclampsia incidence was 21.2%. sTNF-R2 levels were higher at enrollment (P = .02) and weeks 24-28 (P = .01) in women who eventually developed preeclampsia. The magnitude of increase from baseline of both receptors was significantly greater in women who developed preeclampsia in the future. Women with week 24-28 sTNF-R2 levels in the highest quartile had significantly increased odds to develop preeclampsia (P = .03 vs quartile 1). This association was observed in the placebo but not the aspirin arm (P ≤ .002). Sensitivities and positive predictive values were low. Conclusion sTNF-R2 levels are elevated prior to overt preeclampsia, suggesting a pathogenetic role for these proinflammatory cytokines. Soluble receptor levels of tumor necrosis factor (sTNF-R)-1 and -2 are increased during preeclampsia. We postulated the increase preceded overt disease. Archived plasma from the Eunice Kennedy Shriver National Institute of Child Health and Human Development aspirin to prevent preeclampsia in high risk women trial were used to measure serial sTNF-R1 and sTNF-R2 (enrollment, 24-28 week's gestation) in 986 women (577 also sampled at 34-38 weeks). Preeclampsia incidence was 21.2%. sTNF-R2 levels were higher at enrollment (P = .02) and weeks 24-28 (P = .01) in women who eventually developed preeclampsia. The magnitude of increase from baseline of both receptors was significantly greater in women who developed preeclampsia in the future. Women with week 24-28 sTNF-R2 levels in the highest quartile had significantly increased odds to develop preeclampsia (P = .03 vs quartile 1). This association was observed in the placebo but not the aspirin arm (P ≤ .002). Sensitivities and positive predictive values were low. sTNF-R2 levels are elevated prior to overt preeclampsia, suggesting a pathogenetic role for these proinflammatory cytokines." @default.
• W2032568536 created "2016-06-24" @default.
• W2032568536 creator A5003908929 @default.
• W2032568536 creator A5004240332 @default.
• W2032568536 creator A5006614918 @default.
• W2032568536 creator A5019804045 @default.
• W2032568536 creator A5023534305 @default.
• W2032568536 creator A5060078823 @default.
• W2032568536 creator A5061152811 @default.
• W2032568536 creator A5067511554 @default.
• W2032568536 creator A5067641855 @default.
• W2032568536 creator A5075962296 @default.
• W2032568536 creator A5086560462 @default.
• W2032568536 date "2009-06-01" @default.
• W2032568536 modified "2023-10-03" @default.
• W2032568536 title "Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are increased prior to the diagnosis of preeclampsia" @default.
• W2032568536 cites W1964532343 @default.
• W2032568536 cites W1966302891 @default.
• W2032568536 cites W1968036856 @default.
• W2032568536 cites W1973905104 @default.
• W2032568536 cites W1976523980 @default.
• W2032568536 cites W1980247868 @default.
• W2032568536 cites W1980566654 @default.
• W2032568536 cites W1985379157 @default.
• W2032568536 cites W1986023276 @default.
• W2032568536 cites W1993508425 @default.
• W2032568536 cites W2000197014 @default.
• W2032568536 cites W2017673011 @default.
• W2032568536 cites W2064864749 @default.
• W2032568536 cites W2067944326 @default.
• W2032568536 cites W2077070875 @default.
• W2032568536 cites W2077606072 @default.
• W2032568536 cites W2083239040 @default.
• W2032568536 cites W2088657493 @default.
• W2032568536 cites W2089162288 @default.
• W2032568536 cites W2089297528 @default.
• W2032568536 cites W2093829937 @default.
• W2032568536 cites W2097760455 @default.
• W2032568536 cites W2117637609 @default.
• W2032568536 cites W2120926965 @default.
• W2032568536 cites W2176899369 @default.
• W2032568536 cites W2332128238 @default.
• W2032568536 cites W2336449142 @default.
• W2032568536 cites W4211054086 @default.
• W2032568536 cites W4245090795 @default.
• W2032568536 doi "https://doi.org/10.1016/j.ajog.2009.01.033" @default.
• W2032568536 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2862352" @default.
• W2032568536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19306961" @default.
• W2032568536 hasPublicationYear "2009" @default.
• W2032568536 type Work @default.
• W2032568536 sameAs 2032568536 @default.
• W2032568536 citedByCount "25" @default.
• W2032568536 countsByYear W20325685362012 @default.
• W2032568536 countsByYear W20325685362013 @default.
• W2032568536 countsByYear W20325685362014 @default.
• W2032568536 countsByYear W20325685362015 @default.
• W2032568536 countsByYear W20325685362016 @default.
• W2032568536 countsByYear W20325685362017 @default.
• W2032568536 countsByYear W20325685362019 @default.
• W2032568536 countsByYear W20325685362021 @default.
• W2032568536 countsByYear W20325685362022 @default.
• W2032568536 countsByYear W20325685362023 @default.
• W2032568536 crossrefType "journal-article" @default.
• W2032568536 hasAuthorship W2032568536A5003908929 @default.
• W2032568536 hasAuthorship W2032568536A5004240332 @default.
• W2032568536 hasAuthorship W2032568536A5006614918 @default.
• W2032568536 hasAuthorship W2032568536A5019804045 @default.
• W2032568536 hasAuthorship W2032568536A5023534305 @default.
• W2032568536 hasAuthorship W2032568536A5060078823 @default.
• W2032568536 hasAuthorship W2032568536A5061152811 @default.
• W2032568536 hasAuthorship W2032568536A5067511554 @default.
• W2032568536 hasAuthorship W2032568536A5067641855 @default.
• W2032568536 hasAuthorship W2032568536A5075962296 @default.
• W2032568536 hasAuthorship W2032568536A5086560462 @default.
• W2032568536 hasBestOaLocation W20325685362 @default.
• W2032568536 hasConcept C126322002 @default.
• W2032568536 hasConcept C131872663 @default.
• W2032568536 hasConcept C134018914 @default.
• W2032568536 hasConcept C142724271 @default.
• W2032568536 hasConcept C156957248 @default.
• W2032568536 hasConcept C164027704 @default.
• W2032568536 hasConcept C204787440 @default.
• W2032568536 hasConcept C27081682 @default.
• W2032568536 hasConcept C2776914184 @default.
• W2032568536 hasConcept C2777218350 @default.
• W2032568536 hasConcept C2777628954 @default.
• W2032568536 hasConcept C2779234561 @default.
• W2032568536 hasConcept C44249647 @default.
• W2032568536 hasConcept C46973012 @default.
• W2032568536 hasConcept C54355233 @default.
• W2032568536 hasConcept C68443243 @default.
• W2032568536 hasConcept C71924100 @default.
• W2032568536 hasConcept C86803240 @default.
• W2032568536 hasConceptScore W2032568536C126322002 @default.
• W2032568536 hasConceptScore W2032568536C131872663 @default.
• W2032568536 hasConceptScore W2032568536C134018914 @default.
• W2032568536 hasConceptScore W2032568536C142724271 @default.
• W2032568536 hasConceptScore W2032568536C156957248 @default.

• next